Clinical trial · Interventional
Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy
Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-risk Prostate Cancer Treated With Radical Radiotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after radiotherapy to prevent early relapse. This will therefore be tested in a randomised phase III trial where patients will be randomized either to docetaxel or surveillance
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| docetaxel | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Docetaxel arm
- description
- six of docetaxel every third week + hormonal treatment
- interventionNames
- Drug: docetaxel
- type
- NO_INTERVENTION
- label
- Control
- description
- hormonal treatment only
Primary outcomes (1)
- measure
- PSA progression rate
- timeFrame
- From randomization to progression
- description
- According to RTOG-ASTRO guidelines
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Men \> 18 and ≤75 years of age. * WHO/ECOG performance status 0 - 1. * Histological proven adenocarcinoma of the prostate within 12 months prior to randomisation * One of the following: * T2 with Gleason score 7(4+3 ) and PSA \>10 ng/ml to \< 70 ng/ml * T2 with Gleason 8-10, any PSA \< 70 ng/ml * any T3 tumour * Prior neoadjuvant hormone therapy is mandatory for all patients * Adequate haematological-, liver- and kidney function. (Hemoglobin \> 110 g/l, neutrophils \> 1.5 x 109/ l, platelets \> 150 x 109/ l, ASAT and ALAT \< 1.5 x ULN, ALP \< 1.5 x ULN, creatinine \< 1.5 x ULN) * Written informed consent Exclusion Criteria: * M+ * N+ clinical or pathological * Patients with a history of previous malignant disease. Exceptions should be made for basal cell carcinoma (BCC) and squamous cell carcinoma of the skin. Exceptions should also be made for curatively treated malignant disease, which has been disease free for the past five years. * Previous radiotherapy to the pelvic region. * Previous chemotherapy within 5 years. * Systemic corticosteroids within 6 months prior to randomisation. * Unstable cardiovascular disease, including myocardial infarction, within 6 months prior to randomisation. * Active untreated infectious disease, including tuberculosis, MRSA. * Active gastric ulcer. * Known hypersensitivity to Polysorbate 80 (an excipient of docetaxel) * Other serious illness or medical condition
References
Publications (0)
Data not yet available